• FY26 sales revenue at $2.3 billion, 2% increase in constant currency
• Underlying net profit of $322 million, achieving upper end of guidance
• Strategic progress with Nucleus Nexa System launch, R&D investment
• Focus on reducing fixed costs, improving margins
• Expecting low single-digit growth and net profit of $330-350 million in FY27

Cochlear Ltd reported a 2% increase in sales revenue to $2.3 billion in constant currency for FY26, achieving the upper end of revised guidance. Underlying net profit was $322 million. The company launched the Nucleus Nexa System, a smart cochlear implant, and invested in R&D. Cochlear reduced fixed costs to create capacity for growth investments. The company expects low single-digit constant currency sales revenue growth and underlying net profit of $330-350 million in FY27, with gross margin expected to be around 70-71%.

FY27 expected low single-digit sales revenue growth, underlying net profit $330-350 million, gross margin 70-71%

Cochlear remains confident in long-term growth, driven by unmet clinical need and increasing awareness of hearing loss. Expecting modest revenue growth in developed and emerging markets, with services and acoustics revenue growth assumptions.